Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:ADMA NASDAQ:ARWR NASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$76.19-1.9%$70.73$47.86▼$107.37$4.31B0.28511,979 shs785,516 shsADMAADMA Biologics$16.11$17.47$13.50▼$25.67$3.84B0.542.80 million shs3.45 million shsARWRArrowhead Pharmaceuticals$29.72$19.99$9.57▼$31.13$4.11B12.85 million shs3.04 million shsPHARPharming Group$14.68-0.8%$12.09$7.31▼$17.08$1.01B0.0511,026 shs6,812 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+6.84%+7.65%+7.12%+17.70%+4.41%ADMAADMA Biologics+2.22%-4.73%-3.88%-22.59%-4.73%ARWRArrowhead Pharmaceuticals+2.87%+6.14%+66.97%+88.82%+41.93%PHARPharming Group+9.55%-0.47%+30.97%+36.14%+102.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$76.19-1.9%$70.73$47.86▼$107.37$4.31B0.28511,979 shs785,516 shsADMAADMA Biologics$16.11$17.47$13.50▼$25.67$3.84B0.542.80 million shs3.45 million shsARWRArrowhead Pharmaceuticals$29.72$19.99$9.57▼$31.13$4.11B12.85 million shs3.04 million shsPHARPharming Group$14.68-0.8%$12.09$7.31▼$17.08$1.01B0.0511,026 shs6,812 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+6.84%+7.65%+7.12%+17.70%+4.41%ADMAADMA Biologics+2.22%-4.73%-3.88%-22.59%-4.73%ARWRArrowhead Pharmaceuticals+2.87%+6.14%+66.97%+88.82%+41.93%PHARPharming Group+9.55%-0.47%+30.97%+36.14%+102.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.13Buy$114.3150.03% UpsideADMAADMA Biologics 3.33Buy$27.6771.74% UpsideARWRArrowhead Pharmaceuticals 3.00Buy$43.1445.16% UpsidePHARPharming Group 3.00Buy$30.00104.36% UpsideCurrent Analyst Ratings BreakdownLatest PHAR, ACLX, ADMA, and ARWR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.008/11/2025ARWRArrowhead PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.008/8/2025ARWRArrowhead PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $38.008/4/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/31/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$93.00 ➝ $133.007/28/2025ARWRArrowhead PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/17/2025ACLXArcellxCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$110.006/16/2025ACLXArcellxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$115.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M39.15N/AN/A$8.41 per share9.06ADMAADMA Biologics$426.45M9.01$0.54 per share29.76$1.48 per share10.89ARWRArrowhead Pharmaceuticals$3.55M1,157.49N/AN/A$1.54 per share19.30PHARPharming Group$297.20M3.38$0.07 per share199.65$3.25 per share4.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$3.42N/AN/AN/A-329.93%-43.04%-27.41%11/6/2025 (Estimated)ADMAADMA Biologics$197.67M$0.8618.7323.35N/A44.06%41.01%28.47%11/6/2025 (Estimated)ARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)PHARPharming Group-$11.84M-$0.13N/A489.33N/A-2.19%-3.31%-1.78%10/23/2025 (Estimated)Latest PHAR, ACLX, ADMA, and ARWR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 million7/31/2025Q2 2025PHARPharming Group-$0.10$0.06+$0.16$0.06$70.36 million$93.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AADMAADMA BiologicsN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A3.813.81ADMAADMA Biologics0.215.332.78ARWRArrowhead Pharmaceuticals0.394.874.87PHARPharming Group0.382.792.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%ADMAADMA Biologics75.68%ARWRArrowhead Pharmaceuticals62.61%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%ADMAADMA Biologics3.50%ARWRArrowhead Pharmaceuticals4.30%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.46 million50.83 millionOptionableADMAADMA Biologics530238.63 million230.28 millionOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionablePHARPharming Group28068.51 million67.10 millionNot OptionablePHAR, ACLX, ADMA, and ARWR HeadlinesRecent News About These CompaniesPharming Group N.V.: Pharming Group promoted to the Euronext AMX indexSeptember 10 at 5:04 PM | finanznachrichten.dePharming Group promoted to the Euronext AMX® indexSeptember 10 at 6:02 AM | markets.businessinsider.comPharming Group N.V. (PHAR) Presents at H.C. Wainwright 27th Annual Global Investment Conference - SlideshowSeptember 8, 2025 | seekingalpha.comPharming Group (NASDAQ:PHAR) Shares Up 5% - Should You Buy?September 5, 2025 | marketbeat.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Down 73.1% in AugustSeptember 5, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What HappenedSeptember 4, 2025 | marketbeat.comPharming Group to present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | finance.yahoo.comPharming Group names new finance headSeptember 2, 2025 | msn.comPharming Group appoints Kenneth Lynard as Chief Financial OfficerSeptember 2, 2025 | markets.businessinsider.comWall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High?August 22, 2025 | zacks.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short InterestAugust 17, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Trading 1.2% Higher - Still a Buy?August 16, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Should You Buy?August 13, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?August 12, 2025 | marketbeat.comPharming Group NV (PHARMA.XD) - Yahoo FinanceAugust 10, 2025 | finance.yahoo.comWall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a BetAugust 6, 2025 | zacks.comPharming Group N.V. Reports Strong Q2 EarningsAugust 4, 2025 | theglobeandmail.comPharming Group to participate in August investor conferenceAugust 4, 2025 | uk.finance.yahoo.comPharming Group Second Quarter 2025 Earnings: EPS: US$0.007 (vs US$0.002 loss in 2Q 2024)August 2, 2025 | finance.yahoo.comPharming Group N.V. (PHAR) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | seekingalpha.comPharming Group N.V. 2025 Q2 - Results - Earnings Call PresentationAugust 1, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Biotech Catalysts Present Major OpportunityBy Nathan Reiff | August 25, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025Vertical Aerospace: An Analyst's Roadmap to a Potential Re-RatingBy Jeffrey Neal Johnson | August 27, 2025The Uber Eats Partnership Fueling Serve Robotics' GrowthBy Jeffrey Neal Johnson | August 28, 20253 Under-the-Radar Biotechs Under $5 That Could Soar 200%By Chris Markoch | September 9, 2025PHAR, ACLX, ADMA, and ARWR Company DescriptionsArcellx NASDAQ:ACLX$76.19 -1.49 (-1.92%) Closing price 04:00 PM EasternExtended Trading$76.19 0.00 (0.00%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.ADMA Biologics NASDAQ:ADMA$16.11 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$16.10 -0.01 (-0.06%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Arrowhead Pharmaceuticals NASDAQ:ARWR$29.72 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$29.80 +0.08 (+0.27%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Pharming Group NASDAQ:PHAR$14.68 -0.12 (-0.81%) Closing price 04:00 PM EasternExtended Trading$14.42 -0.26 (-1.77%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
